SNARE复合体相关基因与成人ADHD哌甲酯治疗反应
本研究在433例成人ADHD自然样本中评估SNARE复合体相关基因多态性对速释哌甲酯短期反应的影响,272例完成至少30天治疗。SYT1-rs2251214与短期分类反应、注意缺陷和对立违抗症状减分百分比、短期治疗持续性及长期治疗月数相关。
要点
- SYT1-rs2251214与速释哌甲酯短期反应显著相关(P=0.006,PFDR=0.028)。
- 该位点还关联注意缺陷和对立违抗症状减分百分比及治疗持续性。
- 若结果可重复,SytI或为成人ADHD哌甲酯药效学关键要素。
核心结论
- SYT1-rs2251214对成人ADHD速释哌甲酯反应变异性有广泛影响,涉及症状反应和治疗持续性。
研究设计与样本
- 自然样本研究纳入433例成人ADHD受试者,其中272例(62.8%)完成至少30天速释哌甲酯短期治疗。
主要发现
- SYT1-rs2251214与速释哌甲酯短期分类反应相关(P=0.006,PFDR=0.028)。
- SYT1-rs2251214与注意缺陷症状减分百分比相关(P=0.007,PFDR=0.028)。
- SYT1-rs2251214与对立违抗症状减分百分比相关(P=0.017,PFDR=0.048)。
- SYT1-rs2251214与短期治疗持续性相关(P=0.018,PFDR=0.048)。
- SYT1-rs2251214与长期方案中治疗月数相关(P=0.002,PFDR=0.016)。
临床怎么用
- SYT1-rs2251214或可用于提示成人ADHD患者对速释哌甲酯的症状反应和治疗持续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Experimental studies have demonstrated that methylphenidate (MPH) modulates the synaptic vesicle trafficking and synaptotagmin-1 (SytI) mRNA levels. SytI is a regulatory protein of the SNARE complex, a neurotransmitter exocytosis mediator. Despite this evidence, most SNARE complex-related genes have never been evaluated in attention-deficit/hyperactivity disorder (ADHD) pharmacogenetics. This study evaluates, for we believe the first time, polymorphisms on the SNARE complex-related genes STX1A (rs2228607), VAMP2 (26bp Ins/Del) and SYT1 (rs1880867 and rs2251214) on the response to immediate-release methylphenidate (IR-MPH) in a naturalistic sample of adults with ADHD. The sample comprised 433 subjects, of which 272 (62.8%) have completed the short-term IR-MPH treatment (at least 30 days). The main outcome measure was the categorical variable of short-term response to IR-MPH based on the Swanson, Nolan and Pelham Rating Scale version 4 (SNAP-IV), and on the clinical global impression-improvement scale. Additional analyses evaluated the percentage of SNAP-IV symptom reduction for each dimension as well as short- and long- (7 years) term treatment persistence. SYT1-rs2251214 was associated with the categorical short-term response to IR-MPH (P=0.006, PFDR=0.028), and with the percentage of inattention and oppositional defiant disorder symptoms reduction (P=0.007, PFDR=0.028 and P=0.017, PFDR=0.048, respectively). SYT1-rs2251214 was also associated with short-term treatment persistence (P=0.018, PFDR=0.048), and with months of treatment (P=0.002, PFDR=0.016) in the long-term protocol. Our findings suggest that SYT1-rs2251214 presents a broad influence in IR-MPH response variability in adults with ADHD, being involved with both symptom response and treatment persistence. If such findings are replicated, SytI could represent a key element in MPH pharmacodynamics in adults with ADHD.
引用
- da Silva BS, Cupertino RB, Rovaris DL, et al. Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD. Mol Psychiatry. 2017. PMID: 28461697. doi:10.1038/mp.2017.90
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。